

PHASE 2 2017

Objective: Preclinical and mechanistic study

Activities

Activity 2.1 *In vitro* preclinical study on normal and tumor cells

Activity 2.2 Preclinical study in animal models

Activity 2.3 Mechanistic study

Activity 2.4 Co-therapies development

Activity 2.5 Dissemination

Results

Patent request

„Porphyrinic compound for theranostics”, authors: Rica Boscencu, Gina Manda, Radu Petre Socoteanu, Mihail Eugen Hinescu, Ionela Neagoe, Laura Olariu, Brandusa Dumitriu.

Solicitors were from Romania: University of Medicine and Pharmacy „Carol Davila”, Bucharest; “Victor Babes” National Institute of Pathology, Bucharest; „Ilie Murgulescu” Institute of Physical Chemistry, Bucharest; S.C Biotehnos SA Otopeni.

Submitted at OSIM (A/01030/05.12.2017).

Publications

Rica Boscencu, Gina Manda, Natalia Radulea, Radu Petre Socoteanu, Laura Cristina Ceafalan, Ionela Victoria Neagoe, Isabel Ferreira Machado, Selma Huveyda Basaga, Luis Filipe Vieira Ferreira. Studies on the Synthesis, Photophysical and Biological Evaluation of Some Unsymmetrical *Meso*-Tetrasubstituted Phenyl Porphyrins. *Molecules* 2017, 22: 1815; doi:10.3390/molecules22111815. **IF=2.861**

Communications

- 2017 E-MRS Spring Meeting and Exhibit, Symposium K: Bioinspired and biointegrated materials as new frontiers nanomaterials, 22 – 26 May 2017, Strasbourg, Franta

Manda G, Giordani S. Nanomaterials for therapy of redox diseases (oral presentation).

- 44th Congress of the International Society of Oncology and Biomarkers (ISOBM), 7-10 September 2017, Rio de Janeiro, Brasil.

R. Socoteanu, G. Manda, R. Boscencu, M. Anastasescu, G. Vasiliu, L. F. Vieira Ferreira. Unconventional evaluation of some promising A3B porphyrinic type compounds as theranostic agents autori (poster).